List view / Grid view
20 May 2014 | By Novartis
Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States...
Scientists analyzing non-conductive, high-purity materials will soon be able to apply powerful high-resolution glow discharge mass spectrometry (GDMS) to this task. This will open the technique, for example, to analysis of high-purity sapphire used for flat panel displays, ceramics, alumina powder and other desirable applications, including thin-layer depth profiling of…
19 May 2014 | By Roche
Roche announced plans to invest a total of 120 million Swiss francs in the construction of new production facilities in Building 50, an existing building at its Basel site...
19 May 2014 | By Janssen Pharmaceutical Companies
Janssen-Cilag International NV today announced that its next generation protease inhibitor OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C...
19 May 2014 | By The European Medicines Agency
The European Medicines Agency’s Committee for Advanced Therapies and the German Society for Transfusion Medicine and Immunohaematology in collaboration with the German Stem Cell Network are organising a workshop to strengthen dialogue...
19 May 2014 | By AbbVie
AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development and Chief Scientific Officer...
19 May 2014 | By Boehringer Ingelheim
Results from the Phase III INPULSIS™ trials, published online in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in patients with idiopathic pulmonary fibrosis...
16 May 2014 | By Pfizer
Public health initiative aims to increase unacceptably low adult vaccination rates...
16 May 2014 | By Novo Nordisk
Results from the SCALE™ Obesity and Pre-diabetes phase 3a trial will be presented on 16 May, 2014 for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists...
16 May 2014 | By Novartis
Novartis announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License Application for RLX030...
16 May 2014 | By Abbott
Abbott enhances its position in fast-growing Latin American market, more than doubling its branded generics pharmaceutical sales and presence in the region...
15 May 2014 | By Enigma Diagnostics
Enigma Diagnostics Ltd announced a collaboration agreement with China’s National Institute for Communicable Disease Control and Prevention, China Center for Disease Control and Prevention...
15 May 2014 | By Novartis
Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec®...
15 May 2014 | By AstraZeneca
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline...
15 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
